Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX727 or Azacitidine with Durvalumab in HNSCC
NCT03019003Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2017
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of inqovi and azacitidine in squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Change in Immune-based Biomarker Expression at Baseline and 2 Months. Started Mar 2017; status: completed.
02
Drugs
inqoviazacitidine
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03019003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03019003.